Literature DB >> 24389239

Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis.

Ruth Davies1, Ernest Choy2.   

Abstract

Interleukin 6 (IL-6) plays a significant role in many rheumatological diseases and has been described as both a pro- and anti-inflammatory cytokine. IL-6 blockade has been investigated in various rheumatic diseases and a humanised anti-IL-6 receptor antibody has been licensed for use in rheumatoid arthritis, systemic and polyarticular juvenile idiopathic arthritis. The increasing clinical experience of IL-6 blockade in rheumatic diseases adds to the existing knowledge regarding the physiological and pathological roles of IL-6.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IL-6 blockade; Interleukin-6; Pathogenesis; Rheumatology

Mesh：

Substances：

Year:  2014        PMID： 24389239     DOI： 10.1016/j.smim.2013.12.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  10 in total

Review 1.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

Review 2.  Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.

Authors:  Zhihong Zuo; Ting Wu; Liangyu Pan; Chenzhe Zuo; Yingchuo Hu; Xuan Luo; Liping Jiang; Zanxian Xia; Xiaojuan Xiao; Jing Liu; Mao Ye; Meichun Deng
Journal:  Front Pharmacol       Date:  2021-02-08       Impact factor: 5.810

3.  Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study.

Authors:  Bruno Cesar Bacchiega; Ana Beatriz Bacchiega; Magali Justina Gomez Usnayo; Ricardo Bedirian; Gurkirpal Singh; Geraldo da Rocha Castelar Pinheiro
Journal:  J Am Heart Assoc       Date:  2017-03-13       Impact factor: 5.501

Review 4.  Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines.

Authors:  Irene Maeve Rea; David S Gibson; Victoria McGilligan; Susan E McNerlan; H Denis Alexander; Owen A Ross
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

5.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

6.  Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.

Authors:  Sudhir Bhandari; Govind Rankawat; Ajeet Singh
Journal:  Indian J Crit Care Med       Date:  2021-03

7.  Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.

Authors:  Vera S Donnenberg; Patrick L Wagner; James D Luketich; David L Bartlett; Albert D Donnenberg
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 8.  Diagnostic approaches and potential therapeutic options for coronavirus disease 2019.

Authors:  Z Khan; D Ghafoor; A Khan; D Ualiyeva; S A Khan; H Bilal; B Khan; A Khan; W Sajjad
Journal:  New Microbes New Infect       Date:  2020-09-30

Review 9.  SARS-CoV-2 therapeutics: how far do we stand from a remedy?

Authors:  Anurag Singh; Vandana Gupta
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

10.  Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes.

Authors:  Dan Zhang; Rui Guo; Lei Lei; Hongjuan Liu; Yawen Wang; Yili Wang; Hongbo Qian; Tongxin Dai; Tianxiao Zhang; Yanjun Lai; Jingya Wang; Zhiqiang Liu; Tianyan Chen; Aili He; Michael O'Dwyer; Jinsong Hu
Journal:  J Leukoc Biol       Date:  2020-10-11       Impact factor: 6.011
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.